Background: Accumulating evidence has shown that cancer cell metabolism differs from that of normal cells. However, up to now it is not clear whether different cancer types are characterized by a specific metabolite profile. Therefore, this study aims to evaluate whether the plasma metabolic phenotype allows to discriminate between lung and breast cancer.
Results:
The model allows to classify 99% of the breast cancer patients and 93% of the lung cancer patients correctly with an area under the curve (AUC) of 0.96 and can be validated in the independent cohort with a sensitivity of 89%, a specificity of 82% and an AUC of 0.94. Decreased levels of sphingomyelin and phosphatidylcholine ( phospholipids with choline head group) and phospholipids with short, unsaturated fatty acid chains next to increased levels of phospholipids with long, saturated fatty acid chains seem to indicate that cell membranes of lung tumors are more rigid and less sensitive to lipid peroxidation. The other discriminating metabolites are pointing to a more pronounced response of the body to the Warburg effect for lung cancer.
Conclusion: Metabolic phenotyping of plasma allows to discriminate between lung and breast cancer, indicating that the metabolite profile reflects more than a general cancer marker.
Clinical trial registration number: NCT02362776.
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The application of metabolomics in the search for cancer biomarkers has increased enormously over the past years [1] [2] [3] . This discipline comprises the comprehensive analysis of metabolites within a biological system [4] . As metabolites constitute the end products of cellular processes, changes in their concentration reflect alterations in the metabolic phenotype [5] . Metabolomics combines analytical tools such as proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy and multivariate statistics to retrieve diagnostic information regarding diseases. 1 H-NMR spectroscopy allows a fast, noninvasive identification and quantification of complex mixtures of metabolites, as in plasma [4, 6] .
Over the past decade, accumulating evidence has shown that cancer cell metabolism differs from that of normal cells [7] [8] [9] . More specifically, it is reprogrammed to promote cell proliferation and survival and is driven by aberrant signaling pathways induced by the activation of oncogenes/inactivation of tumor suppressor genes [10] . One of the main adaptations of cancer cells is that, even in the presence of normal oxygen levels, they rely on anaerobic energy production through glycolysis, a hallmark known as the Warburg effect [11] .
Previously, we revealed that metabolic phenotyping of plasma enables to discriminate between breast cancer patients and controls [12] . Furthermore, ongoing research of our group is demonstrating, for a large cohort of 450 subjects, that the metabolic phenotype allows to differentiate between lung cancer patients and controls [13] . Nevertheless, until now it is not clear whether the metabolic phenotype reflects a general cancer marker or whether different cancer types have characteristic profiles. Therefore, this study aims to (i) investigate whether the plasma metabolic phenotype allows to discriminate between lung and breast cancer and (ii) evaluate the predictive accuracy of the trained classification model in an independent cohort, next to being of help in understanding the changed metabolism.
patients and methods subjects Lung cancer patients with an adenocarcinoma (n = 145; 55 female and 90 male) were included in the Limburg positron emission tomography (PET) center (n = 105) (Hasselt, Belgium) and at the Department of Respiratory Medicine of University Hospitals Leuven (n = 40) (Leuven, Belgium) from March 2011 to May 2014. The diagnosis of adenocarcinoma was confirmed by a pathological biopsy. Clinical staging was performed according to the 7th edition of the tumor, nodes and metastases classification [14] . Breast cancer patients with an adenocarcinoma (n = 147) were included at the Department of Gynaecology of Ziekenhuis Oost-Limburg (Genk, Belgium) between March 2010 and August 2012. The diagnosis of adenocarcinoma was confirmed by a core needle biopsy. The stage was defined by the revised staging system for breast cancer [15] . For both patient groups, blood sampling and sample preparation was done according to a fixed protocol and by trained staff. Exclusion criteria were: (i) not fasted for at least 6 h; (ii) fasting blood glucose concentration ≥200 mg/dl; (iii) medication intake on the morning of blood sampling and (iv) treatment or history of cancer in the past 5 years. The study was conducted in accordance with the ethical rules of the Helsinki Declaration and Good Clinical Practice and was approved by the involved ethical committees. Study participants provided informed consent.
Both groups were subdivided into a training cohort and a validation cohort (Figure 1 ). More specifically, the 55 female lung cancer patients were assigned to the training cohort, whereas the 90 male lung cancer patients were allocated to the validation cohort in order to examine the confounding effect of gender. Regarding the breast cancer patients, 84 were allocated to the training cohort and 63 to the validation cohort. Five statistical outliers of the training cohort (1 lung cancer patient and 4 breast cancer patients) and 12 of the validation cohort (9 lung cancer patients and 3 breast cancer patients) were excluded. According to their medical files, they showed abnormal concentrations of glucose, lipids or ketone bodies. Individuals with high glucose levels were diagnosed with diabetes or had an increased fasting glucose while those with high lipid levels suffered from obesity, hyperlipidemia or took cholesterol-lowering medication. Most of the individuals with high ketone body levels had a low BMI.
blood sampling and processing
Fasting venous blood was collected in 10 ml lithium-heparin tubes and stored at 4°C within 5 min. Within 8 h after collection, samples were centrifuged at 1600 g for 15 min and plasma aliquots of 500 µl were transferred into cryovials and stored at -80°C.
NMR sample preparation and analysis
After thawing, plasma aliquots were centrifuged at 13 000 g for 4 min at 4°C, followed by diluting 200 µl of the supernatant with 600 µl deuterium oxide containing 0.3 µg/µl trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP) as a chemical shift reference. Samples were placed on ice until 1 H-NMR analysis. After mixing and transferring into 5 mm NMR tubes, the samples were acclimatized to 21.2°during 7 min. The 1 H-NMR spectra were recorded on a 400 MHz (9.4 Tesla) Inova spectrometer (Agilent Technologies Inc.) at 21.2°C . Slightly T 2 -weighted spectra were acquired using the Carr-PurcellMeiboom-Gill pulse sequence (total spin-echo time of 32 ms; interpulse delay of 0.1 ms), preceded by an initial preparation delay of 0. The rational segmentation into 110 regions is based on spiking with known metabolites [12] . The 110 regions were integrated and normalized relative to the total integrated area (except water and TSP), resulting in 110 normalized integration values, being the variables for multivariate statistics.
statistical analysis
Multivariate statistics was performed using SIMCA-P+ (Version 14, Umetrics, Sweden). After mean-centering and Pareto scaling of the variables, unsupervised principal component analysis (PCA) was carried out to identify outliers by a Hotelling's T 2 range test and a distance to model plot. After removing outliers, orthogonal partial least squares discriminant analysis (OPLS-DA) was used to train a classification model. The validity of the model was confirmed by (i) permutation testing, (ii) classifying an independent cohort with a classification cutoff value of 0.5 and (iii) receiver-operating characteristic curve explorer & tester. Via an S-plot, the most discriminating variables and their variable importance for the projection (VIP) values were identified. Variables with a VIP exceeding 0.5 were used to describe the biochemical pathways. Additionally, a Student's t-test corrected for multiple testing by the Benjamini-Hochberg method was applied.
results
Multivariate OPLS-DA statistics was used to train a classification model (classifier) in discriminating between breast and lung cancer based on data input from their metabolic phenotype. The resulting model was validated in an independent cohort. Table 1 shows the characteristics of the training and validation cohorts. However, before starting with OPLS-DA, PCA was conducted to look for possible confounders. Supplementary Figure S1 , available at Annals of Oncology online, shows PCA score plots stained for disease (A), smoking habits (B) and tumor stage (C). The plots demonstrate that smoking habits and tumor stage are no confounders. Applying OPLS-DA on the training set resulted in a model that allows to classify 93% of the 54 female lung cancer patients and 99% of the 80 female breast cancer patients correctly with an area under the curve (AUC) of 0.96 (Table 2, Figure 2A and B). An independent permutation test confirms no overfitting (supplementary Figure S2 , available at Annals of Oncology online). The predictive accuracy of the model was assessed by applying it to the independent cohort of 60 female breast cancer patients and 81 male lung cancer patients (Table 2, Figure 2B and C), resulting in a sensitivity of 89% (89% of the lung cancer patients are correctly classified), a specificity of 82% (82% of the breast cancer patients are correctly classified) and an AUC of 0.94.
Although PCA showed that tumor stage is no confounder, an OPLS-DA model was trained in discriminating between stage I lung cancer patients (n = 27) and stage I breast cancer patients (n = 52) to confirm this. The resulting model classifies 93% of the stage I lung cancer patients and 100% of the stage I breast cancers patients correctly ( Figure 3 , Table 2 ). Hence, it can be concluded that tumor stage is no confounder.
Besides tumor stage, it could be argued that the discrimination is attributable to the fact that most of the breast tumors are estrogen receptor positive (ER + ) and progesterone receptor Table 1 ). To investigate whether discrimination is not due to the predominantly positive hormone receptor status of the breast tumors, the PCA score plot of breast cancer patients was stained for ER and PR status (supplementary Figure S3 , available at Annals of Oncology online). Since ER + and PR + breast tumors do not cluster, the contribution of hormone receptor status to discrimination can be excluded. To affirm this, an OPLS-DA model was trained in discriminating between patients with lung cancer (n = 54) and patients with triple-negative breast cancer [n = 19, ER -, PR -and human epidermal growth factor receptor negative (HER2 -)]. The obtained model classifies 98% of the lung cancer patients and 95% of the patients with triple-negative breast cancer correctly ( Figure 4 , Table 2 ). Therefore, it can be concluded that hormone receptor status is no confounder.
Moreover, in order to examine whether the location of patient inclusion is a confounder, the PCA score plot of lung cancer patients was stained for blood collection location (supplementary Figure S4 , available at Annals of Oncology online). Since patients included in Hasselt (n = 105) and in Leuven (n = 40) do not cluster, location is no confounder. The poor predictive ability (Q2 of 0.11) of the OPLS-DA model trained in differentiating between the 40 patients included in Leuven and a randomly selected equally populated group of patients included in Hasselt confirms this.
To identify the metabolites of which the plasma concentration is increased/decreased in lung cancer patients, only the 50 variables having a VIP value exceeding 0.5 were selected as shown in supplementary Figure S5 , available at Annals of Oncology online. Supplementary Tables S1 and S2, available at Annals of Oncology online, show the variables (and contributing metabolites) which are increased/decreased for lung cancer patients together with their univariate P value and fold change (FC). A positive/negative FC denotes a relatively higher/lower concentration for lung cancer.
The metabolites of which the concentration is increased for lung cancer are glucose, tyrosine, aspartate, threonine, leucine, valine, histidine, methionine, N-acetylated glycoproteins, β-hydroxybutyrate and phospholipids with long, saturated fatty acid chains. Those with decreased concentration include alanine, glutamine, α-ketoglutarate, creatinine, citrate, sphingomyelin and phosphatidylcholine (and other cholinated phospholipids), 
discussion
The rapidly expanding field of metabolomics has been making progress in the area of oncology [16, 17] and studies have explored the disturbed metabolism of lung or breast cancer by 1 H-NMR spectroscopy [12, [18] [19] [20] . However, to our knowledge, this is the first report which examines whether cancer types have specific profiles. Hereto, a homogenous population of patients with an adenocarcinoma was selected. Furthermore, since breast cancer patients were females, only females were included in the training cohort in order to exclude gender as a confounder. This study demonstrates that the metabolic phenotype allows to classify 93% of the female lung cancer patients and 99% of the female breast cancer patients correctly with an AUC of 0.96. Additionally, male lung cancer patients and female breast cancer patients of an independent cohort were classified by the trained classifier with a sensitivity of 89%, a specificity of 82% and an AUC of 0.94, confirming that gender is no confounder. Because cancer cells often outgrow the surrounding vasculature, they have adopted an oxygen-independent metabolism to produce sufficient energy for proliferation. Consequently, cancer cells prefer to convert glucose into lactate rather than oxidizing it via oxidative phosphorylation, a hallmark known as the Warburg effect [11] . Concerning the elevated glycolytic rate in F-FDG) tracer as measured by PET/computed tomography is correlated with metabolic activity and long-term prognosis [21] . Lung tumors display a higher 18 F-FDG uptake than breast tumors, indicating that lung tumors are metabolically more active and by implication more aggressive. A different metabolic activity for lung tumors is supported by altered concentration levels of the membrane phospholipids, i.e. decreased levels of sphingomyelin and phosphatidylcholine and phospholipids with short, unsaturated fatty acid chains, in contrast to increased levels of phospholipids with long, saturated fatty acid chains. As long, saturated chains have very strong Van der Waals interactions, this is indicating that the cell membrane of lung tumors is more rigid and less sensitive to lipid peroxidation [22] . Note however that metabolite concentrations between cancer types are compared and that a decrease for lung cancer when compared with breast cancer might still correspond to an increase relative to controls and vice versa. Remark further that sphingomyelin and phosphatidylcholine can be discriminated from other phospholipids on the basis of the strong NMR signal of the three methyl groups of their choline head group. Furthermore, the increase of phospholipids with long, saturated fatty acid chains can be derived from variable 100 representing CH 2 groups that are separated by at least two carbons from a double bond, and so mainly reflects the relative concentration of phospholipids with long, saturated fatty acid chains. In contrast, variable 110 represents the CH 3 groups and so rather reflects the relative concentration of phospholipids with short, unsaturated fatty acid chains.
Ongoing research of our group in a large cohort of 233 lung cancer patients and 226 controls reveals increased plasma levels of glucose and decreased levels of lactate for lung cancer [13] . These alterations are pointing to the response of the body to the Warburg effect, i.e. hepatic glycogenolysis, gluconeogenesis, ketogenesis, an impaired Krebs cycle and oxidative phosphorylation, rather than the Warburg effect itself (as inside the cancer cell) [13] . Hence, although these findings should be confirmed independently by more dedicated studies, they might point to a more pronounced response of the body to the Warburg effect for lung cancer.
In conclusion, this study reveals that the plasma metabolic phenotype allows to discriminate between lung and breast cancer, indicating that the cancer types studied are characterized by their own, specific metabolite profile. To the best of our knowledge, this has never been published before.
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